BACKGROUND: Ovarian cancer is a gynecologic cancer with a high mortality rate. This shows the need of effective screening methods and reliable cancer markers for ovarian cancer staging and appropriate effective cancer treatment. METHODS: Expression of estrogen receptor alpha and beta was studied by immunhistochemical analysis of 100 ovarian cancer tissue samples. RESULTS: In this study on 100 serous ovarian cancer tissue samples from patients with defined clinicopathologic features, a significant association of ER-alpha expression with ovarian cancer grading (p = 0.004), progression-free survival (p = 0.007), and cause-specific survival (p = 0.001) was demonstrated. Expression of ER-beta was found to be associated with the metastatic lymph node status (p = 0.006). CONCLUSION: Immunohistochemical analysis of ER might be used as an easy, simple and highly efficient marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. Furthermore, patients that show a positive ER-alpha immunostaining can be selected for a specific anti-hormonal therapy, as already performed for breast cancer patients.
BACKGROUND:Ovarian cancer is a gynecologic cancer with a high mortality rate. This shows the need of effective screening methods and reliable cancer markers for ovarian cancer staging and appropriate effective cancer treatment. METHODS: Expression of estrogen receptor alpha and beta was studied by immunhistochemical analysis of 100 ovarian cancer tissue samples. RESULTS: In this study on 100 serous ovarian cancer tissue samples from patients with defined clinicopathologic features, a significant association of ER-alpha expression with ovarian cancer grading (p = 0.004), progression-free survival (p = 0.007), and cause-specific survival (p = 0.001) was demonstrated. Expression of ER-beta was found to be associated with the metastatic lymph node status (p = 0.006). CONCLUSION: Immunohistochemical analysis of ER might be used as an easy, simple and highly efficient marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. Furthermore, patients that show a positive ER-alpha immunostaining can be selected for a specific anti-hormonal therapy, as already performed for breast cancerpatients.
Authors: David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers Journal: Gynecol Oncol Date: 2012-03-06 Impact factor: 5.482
Authors: Stefanie Aust; Anna Bachmayr-Heyda; Petra Pateisky; Dan Tong; Silvia Darb-Esfahani; Carsten Denkert; Radoslav Chekerov; Jalid Sehouli; Sven Mahner; Toon Van Gorp; Ignace Vergote; Paul Speiser; Reinhard Horvat; Robert Zeillinger; Dietmar Pils Journal: Mol Cancer Date: 2012-09-14 Impact factor: 27.401
Authors: Stefanie Aust; Peter Horak; Dietmar Pils; Sophie Pils; Christoph Grimm; Reinhard Horvat; Dan Tong; Bernd Schmid; Paul Speiser; Alexander Reinthaller; Stephan Polterauer Journal: BMC Cancer Date: 2013-03-14 Impact factor: 4.430
Authors: Amy L Shafrir; Ana Babic; Margaret Gates Kuliszewski; Megan S Rice; Mary K Townsend; Jonathan L Hecht; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-20 Impact factor: 4.254
Authors: Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus Journal: Lancet Oncol Date: 2013-07-09 Impact factor: 41.316